Targovax ASA logo

TRVX - Targovax ASA News Story

NOK6.35 -0.0  -0.5%

Last Trade - 3:03pm

Sector
Healthcare
Size
Micro Cap
Market Cap £41.3m
Enterprise Value £35.6m
Revenue £218k
Position in Universe 1022nd / 1786

BRIEF-Targovax Announces Median, Three-Year Overall Survival For TG01 Trial In Resected Pancreatic Cancer

Thu 23rd May, 2019 7:36am
May 23 (Reuters) - Targovax ASA  TRVX.OL :
    * TARGOVAX ANNOUNCES MEDIAN AND THREE-YEAR OVERALL SURVIVAL FOR TG01 TRIAL IN RESECTED
PANCREATIC
CANCER
    * MOS COMPARES FAVORABLY TO ESPAC4 HISTORICAL CONTROL TRIAL OF GEMCITABINE MONOTHERAPY

Source text for Eikon:  ID:nWkrc7VtnH 
Further company coverage:  TRVX.OL 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.